Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (3)
  • Open Access

    ARTICLE

    Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells

    Dong Li*1, Fei-fan Sun*1, Dan Wang*1, Tao Wang*, Jing-jing Peng*, Jian-Qiong Feng*, Hua Li*, Chao Wang, Dai-jun Zhou*, Hong Luo*, Zeng-qiang Fu*, Tao Zhang*

    Oncology Research, Vol.28, No.5, pp. 467-481, 2020, DOI:10.3727/096504020X15925659763817

    Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug… More >

  • Open Access

    CORRECTION

    Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells

    Dong Li*1, Fei-fan Sun*1, Dan Wang*1,Tao Wang*, Jing-jing Peng*, Jian-Qiong Feng*, Hua Li*, Chao Wang, Dai-jun Zhou*, Hong Luo*, Zeng-qiang Fu*, Tao Zhang*

    Oncology Research, Vol.28, No.7-8, pp. 827-828, 2020, DOI:10.3727/096504021X16280937554409

    Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug… More >

  • Open Access

    ARTICLE

    Adhesive Force of Human Hepatoma HepG2 Cells to Endothelial Cells and Expression of E-Selectin

    Guanbin Song∗,†, Toshiro Ohashi, Naoya Sakamoto, Masaaki Sato

    Molecular & Cellular Biomechanics, Vol.3, No.2, pp. 61-68, 2006, DOI:10.3970/mcb.2006.003.061

    Abstract Expression of adhesion molecules may play an important role in the interaction of tumor cells with vascular endothelial cells during tumor invasion and metastasis. In this study, the adhesive force of human hepatoma HepG2 cells to human umbilical vein endothelial cells (HUVECs) was investigated using a micropipette aspiration technique. Expression of an adhesion molecule, E-selectin, was also observed by immunofluorescence microscopy. In particular, the adhesive force after stimulation of HUVECs with recombinant human interleukin-1β (rhIL-1β) was examined. The results demonstrated that the adhesive force of HepG2 cells to stimulated HUVECs is significantly higher than that More >

Displaying 1-10 on page 1 of 3. Per Page